Statera Biopharma, Inc. · OTC:STAB
Statera Biopharma — Cleveland BioLabs — Merger or Acquisition (October 2020)
22 slides from Statera Biopharma's merger presentation, Oct 28, 2020
Slide 1: Discussion of Cytocom and Cleveland BioLabs merger
Jason: Good morning everyone and thank you for joining us to discuss the merger between Cytocom and Cleveland BioLabs. (Next Slide)
Slide 2: Forward-looking statements
- ms shovi reget forma oe Merona om Cag tea Jason: Last week, Cytocom, inc. and Cleveland BioLabs issued a joint press release detailing a strategic merger agreement, which we encourage listeners to read. The press release can be found in the news section of Cytocom.com. Cleveland Biolabs also filed
Slide 3: Introduction of Michael Handley, CEO of Cytocom
new information, future events or otherwise. Joining me on today’s call is Michael Handley, CEO of Cytocom, Inc. , who will discuss the rationale behind the merger with Cleveland BioLabs, and further communicate Cytocom’s vision for the future, as well as expected commercial, regulatory and clinical
Slide 4: Signed Merger Agreement with CBLI
Signed Merger Agreement with CBLI Alstoctransaein cepted o doso Bs quar 2021, subject 0 aproal em CBU shreds thet dosing contin ImQuest Life Sciences Acquisition ‘Syregiscdue polo and CRO pected wo coe tothe closing the CRuimaagse €YTOCOM Nasdaq (CYTO) quty holders in cjtocom wil become majority hol
Slide 5: All-stock transaction expected to close in first quarter 2021
The all-stock transaction to merge with Cleveland BioLabs is expected to close in the first quarter 2021, subject to approval from Cleveland BioLabs stockholders and other closing conditions, including the approval of Nasdaq. The details of the merger can be found in the press release issued last we
Slide 6: Vision and milestones over the next 12 to 18 months
vision for the future and commercial, regulatory and clinical milestones anticipated over the next 12 to 18 months, and hopefully address any outstanding questions. (NEXT SLIDE)
Slide 7: CEO background and experience
For those of you not familiar with Cytocom let me begin by telling you a bit about myself and then the company. | have been a part of the life sciences industry for approximately 25 years, holding positions and taking on roles that have included regulatory and clinical affairs, drug and device comme
Slide 8: Prior roles and Cytocom management team
Prior to joining Cytocom in April 2020, | served as CEO of Armis Biopharma, a multi- product development-stage healthcare company that created a technology platform for the prevention and treatment of topical infectious organisms. Previously, | helped found Vessix Vascular and served on its manageme
Slide 9: Clinical-stage biopharmaceutical company developing novel immunotherapies
Clinical-stage blopharmaceutical company developing novel immunotherapies Spun off from immune Therapeutics inlate 2014 Eradicate mankind's deadliest Immune modulation as a comerstone to druge diseases though the develope mahi ‘AIMS Platform: Targets multiple biological pathways simultaneously with
Slide 10: AIMS platform and Cytocom mission
After years of work with naltrexone and met-enkepahlin and discovering their anti- angiogenic and anti-inflammatory properties, Cytocom developed a proprietary drug discovery and development platform called AIMS ~ Advanced Immunomodulating Multi-receptor System. Through AIMS, we are expanding our un
Slide 11: Cytocom drug development programs
ence i _—<< > || — cesebe 2020 cytocom Right now, three primary drug development programs form the foundation of Cytocom’s internal pipeline -- CYTO-200, CYTO-400 and CYTO-600. We have four assets ready to enter late-stage clinical trials in fibromyalgia, Crohn's disease, multiple sclerosis and panc
Slide 12: Merger and ImQuest to add to R&D efforts
development efforts, as well as our clinical expertise. (NEXT SLIDE)
Slide 13: CBLI Opportunity Overview and synergies
CBLI Opportunity Overview SYNERGIES + 25+ additional patents (parent and + Both companies are focused on subsidiaries) surrounding radiation defense, aging, immunology, : immuno-oncology, diagnostics and homeostasis vaccines + Multiple potential prophylactic * RTL1 and ENL1 inhibitors ae n + TLRS ag
Slide 14: ImQuest acquisition and CRO operations
We expect that the ImQuest acquisition, once completed, will strengthen Cytocom's existing cancer portfolio, as well as its HIV and influenza portfolios, and add new therapeutic areas of focus in hepatitis B and C, and drug resistant microorganisms. But core to ImQuest’s value is its contract resear
Slide 15: ImQuest tools for internal and external drug development
gamechanger for drug makers, and ImQuest has proven its unique capabilities. Cytocom is excited to utilize and further develop these same tools to strengthen our internal drug discovery and development efforts. We also plan to continue offering these same tools to other drug makers. (NEXT SLIDE)
Slide 16: 2021 Q1 Expected Milestones
Now on to our 2021 Q1 Expected Milestones (NEXT SLIDE)
Slide 17: CBLI + CYTO Merger Closing
CBLI+ CYTO Merger Closing + CBLI merger closing expected Ql 2021 + ImQuest acquisition finalized expected Ql 2021 cytocer oY m ss ® Cleveland BioLabs ImQuest N} Genome BioSciences Prscuron FERC Protection In the months to come, Cytocom will be working to close its merger with Cleveland BioLabs, form
Slide 18: Crohn's disease market and Phase 3 plans
‘Type C meeting scheduled to finalize Sequential Therapies for CD Phase 3 Study Phase 2 study supporting Proof of nie Severity at Conceptand Safety Phase 2 Study with remission in 67% and 43% true mucosal healing with endoscopies No serious adverse events reported to date Orphan Drug d Immunomodulat
Slide 19: COVID-19 trial overview
Double-blind randomized, Phase 2 study to evaluate the safety and efficacy of CYTO- 205 to slow or halt the progression of the SARS-CoV-2 infection from mild/moderate (stage 1-2A) to severe (stage 2B-3). CYTO-200 analog in previous human studies dampened harmful inflammation and has the potential to
Slide 20: Future Market Opportunity Overview
cytocem Future Market Opportunity Overview (WAIT FOR MIKE TO SUMMARIZE THEN NEXT SLIDE) 13
Slide 21: Q&A Session
Q&A Session These are exciting times for Cytocom, and we look to the future with a confidence we hope you also share. Again, | would like to thank our employees for their dedication and loyalty along with our stakeholders for their continued support as we evolve and grow in an effort to become one o
Slide 22: Thank You
ThankYou In closing, | appreciate your time and attention and look forward to future updates as we work to close our merger with Cleveland BioLabs, formalize our acquisition of ImQuest Life Sciences and its subsidiaries, and prepare for our potential debut as a publicly traded company. | would also
Cleveland BioLabs — Merger or Acquisition (October 2020) on 6ix